Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: A meta-analysis
- PMID: 30633166
- PMCID: PMC6336640
- DOI: 10.1097/MD.0000000000013923
Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: A meta-analysis
Abstract
Background: In patients with hepatocellular carcinoma (HCC), the clinicopathologic and prognostic roles of tumor-infiltrating CD8+ T cells for survival are still controversial. A meta-analysis was performed to resolve this issue.
Methods: We identified studies from PubMed, Embase, and the Cochrane Library to evaluate the clinicopathologic and prognostic value of tumor-infiltrating CD8+ T cells in patients with HCC. A meta-analysis was conducted to estimate clinicopathologic characteristics, overall survival (OS), and disease-free survival. The hazard ratio (HR) and 95% confidence interval (CI) were calculated employing fixed-effect or random-effect models depending on the heterogeneity of the included trials.
Results: A total of 3509 patients from 21 observational studies were enrolled. The meta-analysis revealed that high levels of intratumoral CD8+ tumor-infiltrating lymphocytes (TILs) were associated with better OS (OS; HR = 0.676, P = .001) and disease-free survival (disease-free survival [DFS]; HR = 0.712, P = .002). The pooled analysis also demonstrated high density of infiltration of CD8+ TILs in margin of tumor (MT) was statistically significant associated with better OS (HR = 0.577; P <.001). Moreover, the patients with low CD8+ TILs infiltration had negative HBSAg (OR = 1.67, P = .02), large tumor size (OR = 1.74, P <.01), and later TNM stage (OR = 1.70, P <.01).
Conclusions: Our findings suggested that low levels of CD8+ TILs predict large tumor size, later TNM stage and might be a promising prognostic factor of HCC especially for Asian patients. High-quality randomized controlled trials are needed to determine if CD8+ TILs could serve as targets for immunotherapy in hepatocellular carcinoma.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures






Similar articles
-
Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A meta-analysis.Medicine (Baltimore). 2018 Dec;97(50):e13301. doi: 10.1097/MD.0000000000013301. Medicine (Baltimore). 2018. PMID: 30557978 Free PMC article. Review.
-
The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis.Sci Rep. 2017 Aug 8;7(1):7525. doi: 10.1038/s41598-017-08128-1. Sci Rep. 2017. PMID: 28790445 Free PMC article.
-
Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis.Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211034265. doi: 10.1177/15330338211034265. Technol Cancer Res Treat. 2021. PMID: 34323154 Free PMC article.
-
The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.Eur J Cancer. 2020 Jun;132:71-84. doi: 10.1016/j.ejca.2020.03.013. Epub 2020 Apr 22. Eur J Cancer. 2020. PMID: 32334338
-
Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis.PLoS One. 2014 May 14;9(5):e94376. doi: 10.1371/journal.pone.0094376. eCollection 2014. PLoS One. 2014. PMID: 24827118 Free PMC article.
Cited by
-
Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma.BMC Cancer. 2020 Sep 29;20(1):937. doi: 10.1186/s12885-020-07105-8. BMC Cancer. 2020. PMID: 32993594 Free PMC article.
-
Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.Front Immunol. 2024 Jan 30;15:1283364. doi: 10.3389/fimmu.2024.1283364. eCollection 2024. Front Immunol. 2024. PMID: 38357542 Free PMC article.
-
Elevated NDC1 expression predicts poor prognosis and correlates with immunity in hepatocellular carcinoma.J Gastrointest Oncol. 2023 Feb 28;14(1):245-264. doi: 10.21037/jgo-22-1166. J Gastrointest Oncol. 2023. PMID: 36915467 Free PMC article.
-
Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.World J Gastrointest Oncol. 2022 Jan 15;14(1):163-180. doi: 10.4251/wjgo.v14.i1.163. World J Gastrointest Oncol. 2022. PMID: 35116109 Free PMC article. Review.
-
New insights on anti-tumor immunity of CD8+ T cells: cancer stem cells, tumor immune microenvironment and immunotherapy.J Transl Med. 2025 Mar 17;23(1):341. doi: 10.1186/s12967-025-06291-y. J Transl Med. 2025. PMID: 40097979 Free PMC article. Review.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin 2015;65:5–29. - PubMed
-
- Rasool M, Rashid S, Arooj M, et al. New possibilities in hepatocellular carcinoma treatment. Anticancer Res 2014;34:1563–71. - PubMed
-
- Hiraoka N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol 2010;15:544–51. - PubMed
-
- Fu J, Zhang Z, Zhou L, et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 2013;58:139–49. - PubMed
-
- Wada Y, Nakashima O, Kutami R, et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998;27:407–14. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials